AI Article Synopsis
- A 38-year-old woman with ACPA-positive rheumatoid arthritis developed symptoms like mild hemolytic anemia and oral ulcers after using an adalimumab biosimilar for 8 months, leading to a diagnosis of Rhupus syndrome.
- Upon switching her medication from GP2017 (adalimumab biosimilar) to infliximab, her anemia and oral ulceration resolved quickly, while low-titer ANA persisted.
- This case is notable as it represents the first reported instance of adalimumab-induced Rhupus syndrome, rather than a traditional drug-induced lupus erythematosus.
Article Abstract
We report a 38-year-old female patient affected with anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) who developed mild hemolytic anemia (Hb = 10.5 vs. >12 gr/dL), indolent oral ulceration, ANA (1:1280, homogeneous pattern), and anti-dsDNA antibody positivity following 8 months of therapy with an adalimumab biosimilar (GP2017). Rhupus syndrome was diagnosed. Replacing GP2017 with infliximab, anemia, oral ulcer, and anti-dsDNA antibodies quickly disappeared, while low-titers (1:80) ANA are still present after more than a year. The possibility that the patient suffered from rhupus rather than drug-induced lupus erythematosus associated to anti-ACPA positivity RA was discussed. To date, after a 14-month follow-up, no manifestations of LE have reappeared. To the best of our knowledge, this is the first report of adalimumab-induced rhupus.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293207 | PMC |
| http://dx.doi.org/10.3390/clinpract11030055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!